Merck partners with King’s College London to develop painkillers
11-03-2019
Biotech firm to use Merck’s CRISPR patents in rodent models
13-12-2018
Artur / iStockphoto.com
German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases (DNA-PK) inhibitors.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Merck Group, Vertex, CRISPR/Cas9, DNA-PK, Belén Garijo, patent licensing, gene editing, oncology
